Read this company snapshot
Daily valuation snapshot
Psyence Biomedical Ltd. Common Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $4.97
- Market capitalization (USD)
- $18,957,210.16
- Price / earnings (TTM)
- Not reported
- Price / book
- 1.12
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research PBM in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research PBM in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing PBM with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $4.97 |
| Market capitalization (USD) | $18,957,210.16 |
| Price / earnings (TTM) | Not reported |
| Price / book | 1.12 |
No matching rows. Clear the filter to see all records.
Read PBM's valuation metrics
Company size
Psyence Biomedical Ltd. Common Shares's recorded market capitalization is $18,957,210.16. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
PBM's recorded price-to-book ratio is 1.12. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Psyence Biomedical Ltd. Common Shares with Aurora
Use the snapshot above to ask a specific question about PBM. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow PBM's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.